YD Bio Ltd (YDES) Form 6-K — Aug 31, 2026
YD Bio reported H1 2026 revenue of $846,501, up 315% from $204,007 a year earlier, and swung to net income of $6.7 million from a prior-year loss of $1.9 million. The profit was driven almost entirely by a $9.8 million non-cash gain from the declining fair value of its warrant liabilities. Underlying operations weakened despite the headline numbers: the operating loss widened 66% to $3.2 million, cash more than halved to $2.7 million from $6.0 million at year-end 2025, and operating activities consumed $2.8 million during the half.
Key figures
- Eps
- 0.09
- Revenue
- 846501
- Net Income
- 6700497
- Revenue Yoy
- 315%
- Cash Position
- 2662004
- Total equity
- 4473969
- Planned 2026 capex
- $9 million to $10 million
- Prior year revenue
- 204007
- Shares outstanding
- 70842844
- Accumulated deficit
- 3537862
- Weighted avg shares
- 70827822
- Fetroja pct of revenue
- 39%
- Ssmc acquisition loi value
- approximately US$26.87 million (NT$839,832,000)
- Yc biotech service revenue
- 66642
- Fetroja single order revenue
- 327060
- Milestones paid to 3d global
- 2820000
- Planned 2026 operating needs
- $2.4 million to $2.7 million
- Warrant liabilities fair value
- 4517421
- Warrant fair value gain noncash
- 9846532
- Operational net loss ex warrants
- 3100000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.